Key result
COVID-19 pandemic linked to ~32% fewer ventricular arrhythmias requiring device therapies vs pre-pandemic periods.
Why the study?
The study was conducted to determine the ventricular arrhythmia burden in patients with implantable cardioverter-defibrillators during the COVID-19 pandemic.
Does the COVID-19 pandemic period reduce ventricular arrhythmia burden in patients with ICDs?
Cohort (n=5,963)
Yes
Does the COVID-19 pandemic period reduce ventricular arrhythmia burden in patients with ICDs?
Effect estimate: IRR 0.68 (95% CI 0.58-0.79)
p-value: p=<0.001
During the COVID-19 pandemic, there was a 32% reduction in ventricular arrhythmias needing device therapies, suggesting a potential role of reduced real-life stressors in ventricular arrhythmia burden.
Should not yet change ICD management; hypothesis-generating for reduced stressors mitigating ventricular arrhythmia burden.
AIMS: Our objective was to determine the ventricular arrhythmia burden in implantable cardioverter-defibrillator (ICD) patients during COVID-19. METHODS AND RESULTS: In this multicentre, observational, cohort study over a 100-day period during the COVID-19 pandemic in the USA, we assessed ventricular arrhythmias in ICD patients from 20 centres in 13 states, via remote monitoring. Comparison was via a 100-day control period (late 2019) and seasonal control period (early 2019). The primary outcome was the impact of COVID-19 on ventricular arrhythmia burden. The secondary outcome was correlation with COVID-19 incidence. During the COVID-19 period, 5963 ICD patients underwent remote monitoring, with 16 942 episodes of treated ventricular arrhythmias (2.8 events per 100 patient-days). Ventricular arrhythmia burden progressively declined during COVID-19 (P < 0.001). The proportion of patients with ventricular arrhythmias amongst the high COVID-19 incidence states was significantly reduced compared with those in low incidence states [odds ratio 0.61, 95% confidence interval (CI) 0.54-0.69, P < 0.001]. Comparing patients remotely monitored during both COVID-19 and control periods (n = 2458), significantly fewer ventricular arrhythmias occurred during COVID-19 [incident rate ratio (IRR) 0.68, 95% CI 0.58-0.79, P < 0.001]. This difference persisted when comparing the 1719 patients monitored during both the COVID-19 and seasonal control periods (IRR 0.69, 95% CI 0.56-0.85, P < 0.001). CONCLUSIONS: During COVID-19, there was a 32% reduction in ventricular arrhythmias needing device therapies, coinciding with measures of social isolation. There was a 39% reduction in the proportion of patients with ventricular arrhythmias in states with higher COVID-19 incidence. These findings highlight the potential role of real-life stressors in ventricular arrhythmia burden in individuals with ICDs. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry; URL: https://www.anzctr.org.au/; Unique Identifier: ACTRN12620000641998.
No takes yet. Share an insight, caveat, or question.
O’Shea et al. (2020) conducted a cohort in Ventricular arrhythmias in patients with implantable cardioverter-defibrillators (n=5,963). COVID-19 pandemic period vs. Pre-pandemic control periods (late 2019 and early 2019) was evaluated on Impact of COVID-19 on ventricular arrhythmia burden (IRR 0.68, 95% CI 0.58-0.79, p=<0.001). The COVID-19 pandemic period was associated with a reduction in ventricular arrhythmias needing device therapies compared to pre-pandemic control periods (IRR 0.68; 95% CI 0.58-0.79; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: